These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 21217174)

  • 1. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and development of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
    PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
    Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
    PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
    Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
    Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
    Zhong W; Gern L; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
    Comstedt P; Schüler W; Meinke A; Lundberg U
    PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
    Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
    J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease.
    Wallich R; Jahraus O; Stehle T; Tran TT; Brenner C; Hofmann H; Gern L; Simon MM
    Eur J Immunol; 2003 Mar; 33(3):708-19. PubMed ID: 12616491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods.
    Wagner B; Freer H; Rollins A; Erb HN; Lu Z; Gröhn Y
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):374-81. PubMed ID: 21890217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.
    Meirelles Richer L; Aroso M; Contente-Cuomo T; Ivanova L; Gomes-Solecki M
    Clin Vaccine Immunol; 2011 Nov; 18(11):1809-16. PubMed ID: 21918116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.